Mast Cells as Drivers of Disease and Therapeutic Targets

被引：98
|
作者：
Siebenhaar, Frank [1 ]
Redegeld, Frank A. [2 ]
Bischoff, Stephan C. [3 ]
Gibbs, Bernhard F. [4 ,5 ]
Maurer, Marcus [1 ]
机构：
[1] Charite, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Utrecht, Div Pharmacol, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands
[3] Univ Hohenheim, Dept Nutr Med & Immunol, Stuttgart, Germany
[4] Univ Kent, Medway Sch Pharm, Canterbury, Kent, England
[5] Carl von Ossietzky Univ Oldenburg, Dept Dermatol & Allergol, Oldenburg, Germany
来源：
TRENDS IN IMMUNOLOGY | 2018年 / 39卷 / 02期
关键词：
RECEPTOR ANTAGONISTS; SYSTEMIC MASTOCYTOSIS; SKIN INFLAMMATION; CATHEPSIN-G; ALLERGEN; DEGRANULATION; INHIBITION; OMALIZUMAB; MEDIATORS; EFFICACY;
D O I：
10.1016/j.it.2017.10.005
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.
引用
收藏
页码：151 / 162
页数：12
相关论文
共 50 条
  • [21] Mast cells as targets for immunotherapy of solid tumors
    Oldford, Sharon A.
    Marshall, Jean S.
    MOLECULAR IMMUNOLOGY, 2015, 63 (01) : 113 - 124
  • [22] Mast Cells as Sources and Targets of Membrane Vesicles
    Shefler, Irit
    Salamon, Pazit
    Hershko, Alon Y.
    Mekori, Yoseph A.
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (34) : 3797 - 3804
  • [23] Therapeutic targets in inflammatory disease
    Hume, DA
    Fairlie, DP
    CURRENT MEDICINAL CHEMISTRY, 2005, 12 (25) : 2925 - 2929
  • [24] Mural Cells: Potential Therapeutic Targets to Bridge Cardiovascular Disease and Neurodegeneration
    Lin, Alexander
    Peiris, Niridu Jude
    Dhaliwal, Harkirat
    Hakim, Maria
    Li, Weizhen
    Ganesh, Subramaniam
    Ramaswamy, Yogambha
    Patel, Sanjay
    Misra, Ashish
    CELLS, 2021, 10 (03) : 1 - 25
  • [25] Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
    Jing Hua Zhao
    David Stacey
    Niclas Eriksson
    Erin Macdonald-Dunlop
    Åsa K. Hedman
    Anette Kalnapenkis
    Stefan Enroth
    Domenico Cozzetto
    Jonathan Digby-Bell
    Jonathan Marten
    Lasse Folkersen
    Christian Herder
    Lina Jonsson
    Sarah E. Bergen
    Christian Gieger
    Elise J. Needham
    Praveen Surendran
    Dirk S. Paul
    Ozren Polasek
    Barbara Thorand
    Harald Grallert
    Michael Roden
    Urmo Võsa
    Tonu Esko
    Caroline Hayward
    Åsa Johansson
    Ulf Gyllensten
    Nick Powell
    Oskar Hansson
    Niklas Mattsson-Carlgren
    Peter K. Joshi
    John Danesh
    Leonid Padyukov
    Lars Klareskog
    Mikael Landén
    James F. Wilson
    Agneta Siegbahn
    Lars Wallentin
    Anders Mälarstig
    Adam S. Butterworth
    James E. Peters
    Nature Immunology, 2023, 24 : 1540 - 1551
  • [26] Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
    Zhao, Jing Hua
    Stacey, David
    Eriksson, Niclas
    Macdonald-Dunlop, Erin
    Hedman, Asa K.
    Kalnapenkis, Anette
    Enroth, Stefan
    Cozzetto, Domenico
    Digby-Bell, Jonathan
    Marten, Jonathan
    Folkersen, Lasse
    Herder, Christian
    Jonsson, Lina
    Bergen, Sarah E.
    Gieger, Christian
    Needham, Elise J.
    Surendran, Praveen
    Metspalu, Andres
    Milani, Lili
    Magi, Reedik
    Nelis, Mari
    Hudjasov, Georgi
    Paul, Dirk S.
    Polasek, Ozren
    Thorand, Barbara
    Grallert, Harald
    Roden, Michael
    Vosa, Urmo
    Esko, Tonu
    Hayward, Caroline
    Johansson, Asa
    Gyllensten, Ulf
    Powell, Nick
    Hansson, Oskar
    Mattsson-Carlgren, Niklas
    Joshi, Peter K.
    Danesh, John
    Padyukov, Leonid
    Klareskog, Lars
    Landen, Mikael
    Wilson, James F.
    Siegbahn, Agneta
    Wallentin, Lars
    Malarstig, Anders
    Butterworth, Adam S.
    Peters, James E.
    NATURE IMMUNOLOGY, 2023, 24 (09) : 1540 - +
  • [27] CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
    Noorani, Imran
    Bradley, Allan
    de la Rosa, Jorge
    GENOME BIOLOGY, 2020, 21 (01)
  • [28] Microbiota as Drivers and as Therapeutic Targets in Ocular and Tissue Specific Autoimmunity
    Salvador, Ryan
    Zhang, Amy
    Horai, Reiko
    Caspi, Rachel R.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 8
  • [29] Molecular Drivers and Therapeutic Targets for Neuroendocrine Transformation in Lung Cancer
    Sen, T.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S47 - S47
  • [30] CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
    Imran Noorani
    Allan Bradley
    Jorge de la Rosa
    Genome Biology, 21
12345